Immunotherapy: A useful strategy to help combat multidrug resistance

Drug Resistance Updates

Volumn 15, Issue 1-2, 2012, Pages 106-113

  Curiel, Tyler J ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Combination therapy; Cytokines; Immune dysfunction; Immunotherapy; Multidrug resistance

Indexed keywords

ALEMTUZUMAB; ALPHA INTERFERON; ANTHRACYCLINE; CYCLOPHOSPHAMIDE; CYTOKINE; CYTOTOXIC AGENT; DACARBAZINE; DOXORUBICIN; FLUDARABINE; FLUOROURACIL; IDARUBICIN; IMMUNOTOXIN; INTERLEUKIN 2; MITOXANTRONE; OXALIPLATIN; RITUXIMAB; SORAFENIB; SUNITINIB; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ADAPTIVE IMMUNITY; ANTIBODY PRODUCTION; CANCER IMMUNOTHERAPY; CANCER RESISTANCE; CHRONIC LYMPHATIC LEUKEMIA; CYTOTOXICITY; HUMAN; IMMUNITY; IMMUNOGENICITY; INFLAMMATION; INNATE IMMUNITY; KIDNEY CARCINOMA; MELANOMA; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; REVIEW; TUMOR MICROENVIRONMENT;

EID: 84860687790     PISSN: 13687646     EISSN: 15322084     Source Type: Journal    
DOI: 10.1016/j.drup.2012.03.003     Document Type: Article

References (69)

1. M. Aluigi, D. Debernardis, G. Cimoli, C. Ottoboni, S. Parodi, and P. Russo Tumor-necrosis-factor and DNA topoisomerase-ii inhibitors in human ovarian-cancer - potential role in chemotherapy Int. J. Oncol. 7 1995 461 467
2. L. Apetoh, C. Locher, F. Ghiringhelli, G. Kroemer, and L. Zitvogel Harnessing dendritic cells in cancer Semin. Immunol. 23 2011 42 49
3. L. Apetoh, G. Mignot, T. Panaretakis, G. Kroemer, and L. Zitvogel Immunogenicity of anthracyclines: moving towards more personalized medicine Trends Mol. Med. 14 2008 141 151
4. L. Apetoh, A. Tesniere, F. Ghiringhelli, G. Kroemer, and L. Zitvogel Molecular interactions between dying tumor cells and the innate immune system determine the efficacy of conventional anticancer therapies Cancer Res. 68 2008 4026 4030
5. A.K. Azab, J.M. Runnels, C. Pitsillides, A.S. Moreau, F. Azab, and X. Leleu CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy Blood 113 2009 4341 4351
6. D. Berd, and M.J. Mastrangelo Effect of low dose cyclophosphamide on the immune system of cancer patients: depletion of CD4+, 2H4+ suppressor-inducer T-cells Cancer Res. 48 1988 1671 1675
7. S. Bierer, I. Hoffmeister, J. Gerss, E. Herrmann, C. Wulfing, and W. Sibrowski Combined immunochemotherapy in selected patients with metastatic renal cell carcinoma: HLA class II genotype can help to predict response to therapy J. Immunother. 34 2011 196 201
8. N. Casares, M.O. Pequignot, A. Tesniere, F. Ghiringhelli, S. Roux, and N. Chaput Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death J. Exp. Med. 202 2005 1691 1701
9. V. Cenni, N.M. Maraldi, A. Ruggeri, P. Secchiero, R. Del Coco, and A. De Pol Sensitization of multidrug resistant human ostesarcoma cells to Apo2 Ligand/TRAIL-induced apoptosis by inhibition of the Akt/PKB kinase Int. J. Oncol. 25 2004 1599 1608
10. T.J. Curiel Regulatory T cells and treatment of cancer Curr. Opin. Immunol. 20 2008 241 246
11. T.J. Curiel Tregs and rethinking cancer immunotherapy J. Clin. Invest. 117 2007 1167 1174
12. N. D'Alessandro, A. Flugy, M. Tolomeo, and L. Dusonchet The apoptotic signaling of TNF-alpha in multidrug resistant Friend leukemia cells Anticancer Res. 18 1998 3065 3072
13. K. Fischer, P. Cramer, R. Busch, S. Stilgenbauer, J. Bahlo, and C.D. Schweighofer Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the german chronic lymphocytic leukemia study group J. Clin. Oncol. 29 2011 3559 3566
14. E.N. Fish The X-files in immunity: sex-based differences predispose immune responses Nat. Rev. Immunol. 8 2008 737 744
15. C. Folkins, S. Man, P. Xu, Y. Shaked, D.J. Hicklin, and R.S. Kerbel Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors Cancer Res. 67 2007 3560 3564
16. D.I. Gabrilovich, and S. Nagaraj Myeloid-derived suppressor cells as regulators of the immune system Nat. Rev. Immunol. 9 2009 162 174
17. G. Gatouillat, J. Odot, E. Balasse, C. Nicolau, P.F. Tosi, and D.T. Hickman Immunization with liposome-anchored pegylated peptides modulates doxorubicin sensitivity in P-glycoprotein-expressing P388 cells Cancer Lett. 257 2007 165 171
18. F. Ghiringhelli, C. Menard, P.E. Puig, S. Ladoire, S. Roux, and F. Martin Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients Cancer Immunol. Immunother. 56 2007 641 648
19. I. Grodzovski, M. Lichtenstein, H. Galski, and H. Lorberboum-Galski IL-2-granzyme A chimeric protein overcomes multidrug resistance (MDR) through a caspase 3-independent apoptotic pathway Int. J. Cancer 128 2010 1966 1980
20. H. Guo, W. Jiang, W. Liu, Y. Gao, M. Yang, and Y. Zhou Extracellular domain of 4-1BBL enhanced the antitumoral efficacy of peripheral blood lymphocytes mediated by anti-CD3 x anti-Pgp bispecific diabody against human multidrug-resistant leukemia Cell Immunol. 251 2008 102 108
21. P.B. Gupta, C.L. Chaffer, and R.A. Weinberg Cancer stem cells: mirage or reality? Nat. Med. 15 2009 1010 1012
22. P.B. Gupta, T.T. Onder, G. Jiang, K. Tao, C. Kuperwasser, and R.A. Weinberg Identification of selective inhibitors of cancer stem cells by high-throughput screening Cell 138 2009 645 659
23. J.L. Hao, P.J. Cozzi, A. Khatri, C.A. Power, and Y. Li CD147/EMMPRIN and CD44 are potential therapeutic targets for metastatic prostate cancer Curr. Cancer Drug Targets 10 2010 287 306
24. G. Hartmann, H. Kim, and M. Piquette-Miller Regulation of the hepatic multidrug resistance gene expression by endotoxin and inflammatory cytokines in mice Int. Immunopharmacol. 1 2001 189 199
25. D. Herrmann, G. Seitz, S.W. Warmann, M. Bonin, J. Fuchs, and S. Armeanu-Ebinger Cetuximab promotes immunotoxicity against rhabdomyosarcoma in vitro J. Immunother. 33 2010 279 286
26. X.F. Hu, J. Li, E. Yang, S. Vandervalk, and P.X. Xing Anti-Cripto Mab inhibit tumour growth and overcome MDR in a human leukaemia MDR cell line by inhibition of Akt and activation of JNK/SAPK and bad death pathways Br. J. Cancer 96 2007 918 927
27. Y. Huang, Y. Wang, Y. Li, K. Guo, and Y. He Role of sorafenib and sunitinib in the induction of expressions of NKG2D ligands in nasopharyngeal carcinoma with high expression of ABCG2 J. Cancer Res. Clin. Oncol. 137 2010 829 837
28. V. Hurez, B.J. Daniel, L. Sun, A.-J. Liu, S.M. Ludwig, and M.J. Kious Mitigating age-related immune dysfunction heightens the efficacy of tumor immunotherapy in aged mice Cancer Research 2012 in press
29. J. Ji, K.L. Black, and J.S. Yu Glioma stem cell research for the development of immunotherapy Neurosurg. Clin. N. Am. 21 2009 159 166
30. R.W. Johnstone, A.A. Ruefli, K.M. Tainton, and M.J. Smyth A role for P-glycoprotein in regulating cell death Leuk. Lymphoma 38 2000 1 11
31. D.Y. Kim, M.J. Kim, H.B. Kim, J.W. Lee, J.H. Bae, and D.W. Kim Suppression of multidrug resistance by treatment with TRAIL in human ovarian and breast cancer cells with high level of c-Myc Biochim. Biophys. Acta 1812 2011 796 805
32. R. Komdeur, B.E. Plaat, H.J. Hoekstra, W.M. Molenaar, H. Hollema, and E. van den Berg Expression of P-glycoprotein, multidrug resistance-associated protein 1, and lung resistance-related protein in human soft tissue sarcomas before and after hyperthermic isolated limb perfusion with tumor necrosis factor-alpha and melphalan Cancer 91 2001 1940 1948
33. C.T. Kuan, N. Srivastava, R.E. McLendon, W.A. Marasco, M.R. Zalutsky, and D.D. Bigner Recombinant single-chain variable fragment antibodies against extracellular epitopes of human multidrug resistance protein MRP3 for targeting malignant gliomas Int. J. Cancer 127 2009 598 611
34. P.Y. Lin, L. Sun, S.R. Thibodeaux, S.M. Ludwig, R.K. Vadlamudi, and V.J. Hurez B7-H1-dependent sex-related differences in tumor immunity and immunotherapy responses J. Immunol. 185 2010 2747 2753
35. M.T. Litzinger, R. Fernando, T.J. Curiel, D.W. Grosenbach, J. Schlom, and C. Palena IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunity Blood 110 2007 3192 3201
36. P. Liu, L. Chen, and X. Huang The antitumor effects of CIK cells combined with docetaxel against drug-resistant lung adenocarcinoma cell line SPC-A1/DTX in vitro and in vivo Cancer Biother. Radiopharm. 24 2009 91 98
37. J.P. Machiels, R.T. Reilly, L.A. Emens, A.M. Ercolini, R.Y. Lei, and D. Weintraub Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice Cancer Res. 61 2001 3689 3697
38. H. Matsui, A. Takeshita, K. Naito, K. Shinjo, K. Shigeno, and M. Maekawa Reduced effect of gemtuzumab ozogamicin (CMA-676) on P-glycoprotein and/or CD34-positive leukemia cells and its restoration by multidrug resistance modifiers Leukemia 16 2002 813 819
39. D.F. McDermott The application of high-dose interleukin-2 for metastatic renal cell carcinoma Med. Oncol. 26 Suppl. 1 2009 13 17
40. E. Mizukoshi, M. Honda, K. Arai, T. Yamashita, Y. Nakamoto, and S. Kaneko Expression of multidrug resistance-associated protein 3 and cytotoxic T cell responses in patients with hepatocellular carcinoma J. Hepatol. 49 2008 946 954
41. F. Mosaffa, F. Kalalinia, B.H. Parhiz, and J. Behravan Tumor necrosis factor alpha induces stronger cytotoxicity in ABCG2-overexpressing resistant breast cancer cells compared with their drug-sensitive parental line DNA Cell Biol. 30 2011 413 418
42. M. Obeid, A. Tesniere, F. Ghiringhelli, G.M. Fimia, L. Apetoh, and J.L. Perfettini Calreticulin exposure dictates the immunogenicity of cancer cell death Nat. Med. 13 2007 54 61
43. K.E. Odening, W. Li, R. Rutz, S. Laufs, S. Fruehauf, and Z. Fishelson Enhanced complement resistance in drug-selected P-glycoprotein expressing multi-drug-resistant ovarian carcinoma cells Clin. Exp. Immunol. 155 2009 239 248
44. S.A. Parikh, M.J. Keating, S. O'Brien, X. Wang, A. Ferrajoli, and S. Faderl Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemia Blood 118 2011 2062 2068
45. S.J. Park, C.H. Wu, M.R. Choi, F. Najafi, A. Emami, and A.R. Safa P-glycoprotein enhances TRAIL-triggered apoptosis in multidrug resistant cancer cells by interacting with the death receptor DR5 Biochem. Pharmacol. 72 2006 293 307
46. R.T. Prehn, and J.M. Main Immunity to methylcholanthrene-induced sarcomas J. Natl. Cancer Inst. 18 1957 769 778
47. V. Radojcic, K.B. Bezak, M. Skarica, M.A. Pletneva, K. Yoshimura, and R.D. Schulick Cyclophosphamide resets dendritic cell homeostasis and enhances antitumor immunity through effects that extend beyond regulatory T cell elimination Cancer Immunol. Immunother. 59 2010 137 148
48. J.C. Riches, A.G. Ramsay, and J.G. Gribben Chronic lymphocytic leukemia: an update on biology and treatment Curr. Oncol. Rep. 13 2011 379 385
49. R.B. Rowswell-Turner, J.L. Harden, R.E. Nair, T. Gu, M.O. Kilinc, and N.K. Egilmez Chronic chemoimmunotherapy achieves cure of spontaneous murine mammary tumors via persistent blockade of posttherapy counter-regulation J. Immunol. 187 2011 4109 4118
50. P. Secchiero, M. Vaccarezza, A. Gonelli, and G. Zauli TNF-related apoptosis-inducing ligand (TRAIL): a potential candidate for combined treatment of hematological malignancies Curr. Pharm. Des. 10 2004 3673 3681
51. S.B. Seo, J.G. Hur, M.J. Kim, J.W. Lee, H.B. Kim, and J.H. Bae TRAIL sensitize MDR cells to MDR-related drugs by down-regulation of P-glycoprotein through inhibition of DNA-PKcs/Akt/GSK-3beta pathway and activation of caspases Mol. Cancer 9 2011 199
52. G.V. Shurin, I.L. Tourkova, R. Kaneno, and M.R. Shurin Chemotherapeutic agents in noncytotoxic concentrations increase antigen presentation by dendritic cells via an IL-12-dependent mechanism J. Immunol. 183 2009 137 144
53. U. Stein, W. Walther, R.H. Shoemaker, and P.M. Schlag IL-2 gene transfer for chemosensitization of multidrug-resistant human colon carcinoma cells Adv. Exp. Med. Biol. 451 1998 145 149
54. R.M. Steinman, and J. Banchereau Taking dendritic cells into medicine Nature 449 2007 419 426
55. E. Suzuki, V. Kapoor, A.S. Jassar, L.R. Kaiser, and S.M. Albelda Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity Clin. Cancer Res. 11 2005 6713 6721
56. A.A. Tarhini, J.M. Kirkwood, W.E. Gooding, S. Moschos, and S.S. Agarwala A phase 2 trial of sequential temozolomide chemotherapy followed by high-dose interleukin 2 immunotherapy for metastatic melanoma Cancer 113 2008 1632 1640
57. B.J. Taylor, D.P. Olson, and S.P. Ivy Detection of P-glycoprotein in cell lines and leukemic blasts: failure of select monoclonal antibodies to detect clinically significant Pgp levels in primary cells Leuk. Res. 25 2001 1127 1135
58. A. Tesniere, L. Apetoh, F. Ghiringhelli, N. Joza, T. Panaretakis, and O. Kepp Immunogenic cancer cell death: a key-lock paradigm Curr. Opin. Immunol. 20 2008 504 511
59. R.S. Treichel, M. Bunuan, N. Hahn, and K. Wee Altered conjugate formation and altered apoptosis of multidrug-resistant human leukemia cell line affects susceptibility to killing by activated natural killer (NK) cells Int. J. Cancer 108 2004 78 85
60. J. Vincent, G. Mignot, F. Chalmin, S. Ladoire, M. Bruchard, and A. Chevriaux 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity Cancer Res. 70 2010 3052 3061
61. C. Visus, Y.Y. Wang, A. Lozano-Leon, R.L. Ferris, S. Silver, and M.J. Szczepanski Targeting ALDH(bright) human carcinoma-initiating cells with ALDH1A1-specific CD8+ T cells Clin. Cancer Res. 17 2011 6174 6184
62. J.E. Visvader, and G.J. Lindeman Cancer stem cells in solid tumours: accumulating evidence and unresolved questions Nat. Rev. Cancer 8 2008 755 768
63. W. Walther, and U. Stein Influence of cytokines on mdr1 expression in human colon carcinoma cell lines: increased cytotoxicity of MDR relevant drugs J. Cancer Res. Clin. Oncol. 120 1994 471 478
64. W. Walther, U. Stein, I. Fichtner, M. Alexander, R.H. Shoemaker, and P.M. Schlag Mdr1 promoter-driven tumor necrosis factor-alpha expression for a chemotherapy-controllable combined in vivo gene therapy and chemotherapy of tumors Cancer Gene Ther. 7 2000 893 900
65. G. Xu, X. Wen, Y. Hong, H. Du, X. Zhang, and J. Song An anti-transferrin receptor antibody enhanced the growth inhibitory effects of chemotherapeutic drugs on human glioma cells Int. Immunopharmacol. 11 2011 1844 1849
66. Q. Zhao, H. Zhang, Y. Li, J. Liu, X. Hu, and L. Fan Anti-tumor effects of CIK combined with oxaliplatin in human oxaliplatin-resistant gastric cancer cells in vivo and in vitro J. Exp. Clin. Cancer Res. 29 2010 118
67. L. Zitvogel, and G. Kroemer Anticancer immunochemotherapy using adjuvants with direct cytotoxic effects J. Clin. Invest. 119 2009 2127 2130
68. L. Zitvogel, A. Tesniere, and G. Kroemer Cancer despite immunosurveillance: immunoselection and immunosubversion Nat. Rev. Immunol. 6 2006 715 727
69. W. Zou Regulatory T cells, tumour immunity and immunotherapy Nat. Rev. Immunol. 6 2006 295 307